STEAP3 Affects Ferroptosis and Progression of Renal Cell Carcinoma Through the p53/xCT Pathway

Area of Science:

• Oncology
• Cell Death Mechanisms
• Molecular Biology

Background:

• Renal cell carcinoma (RCC) exhibits sensitivity to ferroptosis, an iron-dependent cell death pathway distinct from apoptosis.
• The STEAP3 gene, known to influence apoptosis in prostate cancer, has an unelucidated role in RCC.
• Understanding novel cell death pathways and their regulators is crucial for advancing RCC treatment strategies.

Purpose of the Study:

• To investigate the role of STEAP3 in renal cell carcinoma (RCC).
• To determine the relationship between STEAP3 expression and patient prognosis in RCC.
• To explore the impact of STEAP3 on ferroptosis sensitivity in RCC cells.

Main Methods:

• Real-time quantitative polymerase chain reaction (RT-qPCR) to assess STEAP3 gene expression in RCC tissues and cell lines.
• Immunohistochemistry to evaluate STEAP3 protein expression levels.
• STEAP3 knockdown experiments followed by treatment with erastin (a ferroptosis inducer) to assess ferroptosis sensitivity.
• Analysis of the p53/xCT pathway involvement.

Main Results:

• STEAP3 gene expression was significantly upregulated in RCC tissues and cell lines compared to normal controls.
• High STEAP3 expression correlated with poorer patient survival and prognosis.
• Knockdown of STEAP3 in RCC cells increased their susceptibility to ferroptosis.
• The observed effect of STEAP3 knockdown on ferroptosis was mediated through the p53/xCT pathway.

Conclusions:

• STEAP3 is upregulated in renal cell carcinoma and is associated with adverse patient outcomes.
• STEAP3 plays a role in regulating ferroptosis in RCC, potentially through the p53/xCT pathway.
• Targeting STEAP3 represents a promising therapeutic strategy for enhancing ferroptosis-induced cell death in renal cell carcinoma.